ANAHEIM, Calif., BioProcess International 2008, Booth 200A, Sept. 23, 2008 -- Agilent Technologies Inc. (NYSE: A) today introduced its Bio-Monolith HPLC columns here at the BioProcess International meeting, which runs through Sept. 26. The Agilent Bio-Monolith HPLC Columns provide high-resolution and rapid separations of large proteins, antibodies (IgG, IgM), plasmid DNA, viruses, phages and other macro bio-molecules.
“Agilent’s Bio-Monolith HPLC columns will greatly improve QA/QC and process monitoring of many bio-molecules being developed in the areas of gene therapy, vaccine development and biologic-based therapeutics research,” said Helen Stimson, vice president and general manager of Agilent’s Global Columns and Supplies Solutions.
The columns contain a short, polymer-based, monolith disc that allows for “flow rate independent” separations. The monolith structure virtually eliminates diffusion; there are no pores and no void volumes, making transport between mobile and stationary phase very rapid. The column family offers strong cation exchange, strong and weak anion exchange, and Protein A phases. Bio-Monolith HPLC columns are compatible with HPLC and preparative LC systems, including Agilent 1100 and 1200 HPLC systems.
Agilent Bio-Monolith HPLC columns are available now. For more information about the columns, please visit www.agilent.com/chem/biomonolith or visit Agilent at Booth 200A. For more information about Agilent’s HPLC systems and other Analytical Bio-Columns please visit www.chem.agilent.com.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 20,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.4 billion in fiscal 2007. Information about Agilent is available on the Web at www.agilent.com.
